SEC Form 4 · accession 0000899866-15-000125
ALEXION PHARMACEUTICALS, INC. · ALXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martin Mackay
Officer — EVP & Global Head of R&D
Period of report
May 14, 2015
Accepted (ET)
May 22, 2015 · 5:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899866
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.0001 per shareF1 | May 14, 2015 | S | 4,056 | $160.33 | D | 32,893 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.